A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in combination with methotrexate in patients who do not respond satisfactorily to standard treatment, e.g. methotrexate.
Epistemonikos ID: 255d93a08d08b2df98c8d00cfb53a9fc885beff2
First added on: Mar 23, 2022